Back to Search Start Over

Statement Regarding the Pre and Post Market Assessment of Durable, Implantable Ventricular Assist Devices in the United States: Executive Summary

Authors :
Steven W. Boyce
Michael A. Acker
Stephen Westaby
Peter D. Wearden
David C. Naftel
Jeffrey J. Teuteberg
Keith D. Aaronson
Randall C. Starling
Leslie W. Miller
Clyde W. Yancy
Douglas L. Mann
Timothy Baldwin
Francis D. Pagani
Robert L. Kormos
Elizabeth D. Blume
Joseph G. Rogers
Mark S. Slaughter
Lynne W. Stevenson
Bartley P. Griffith
Robert S.D. Higgins
Michael J. Mack
Mariell Jessup
Wendy Gattis Stough
Source :
The Annals of Thoracic Surgery. 94:e163-e168
Publication Year :
2012
Publisher :
Elsevier BV, 2012.

Abstract

The incorporation of complex medical device technologies into clinical practice is governed by critical oversight of the US Food and Drug Administration. This regulatory process requires a judicious balance between assuring safety and efficacy, while providing efficient review to facilitate access to innovative therapies. Recent contrasting views of the regulatory process have emphasized the difficulties in obtaining an optimal balance. Mechanical circulatory support has evolved to become an important therapy for patients with advanced heart failure with the advent of more durable, implantable ventricular assist devices. The regulatory oversight of these new technologies has been difficult owing to the complexities of these devices, associated adverse event profile, and severity of illness of the intended patient population. Maintaining a regulatory environment to foster efficient introduction of safe and effective technologies is critical to the success of ventricular assist device therapy and the health of patients with advanced heart failure. Physicians representing key surgical and cardiology societies, and representatives from the Food and Drug Administration, National Heart, Lung, and Blood Institute, Centers for Medicare and Medicaid Services, Interagency Registry of Mechanically Assisted Circulatory Support, and industry partners gathered to discuss relevant issues regarding the current regulatory environment assessing ventricular assist devices. The goal of the meeting was to explore innovative ways to foster the introduction of technologically advanced, safe, and effective ventricular assist devices. The following summary reflects opinions and conclusions endorsed by The Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, Heart Failure Society of America, International Society for Heart and Lung Transplantation, and the Interagency Registry of Mechanically Assisted Circulatory Support.

Details

ISSN :
00034975
Volume :
94
Database :
OpenAIRE
Journal :
The Annals of Thoracic Surgery
Accession number :
edsair.doi.dedup.....e3e5b61e582f6b2768be667063c6457d